Advertisement

Topics

Kyowa Hakko Kirin Co. Ltd. Company Profile

08:39 EDT 19th June 2018 | BioPortfolio


News Articles [114 Associated News Articles listed on BioPortfolio]

Kyowa Kirin und Ultragenyx geben bekannt, dass Crysvita® (Burosumab) eine bedingte Zulassung ...

Kyowa Hakko Kirin Co. Ltd, (Kyowa Hakko Kirin), Kyowa Kirin International PLC (Kyowa Kirin International) und Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE: Ultragenyx) gaben Read more...

Kyowa Hakko Kirin Announces FDA Notification of PDUFA Action Date Extension for Mogamulizumab

Tokyo, Japan, May 30, 2018 –Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151 President and COO: Masashi Miyamoto, “Kyowa Hakko Kirin”) announced today that it has been notified that the U.S. Food and Dr...

Crysvita Meets Primary Endpoint in Phase 3 Trial in Children with X-Linked Hypophosphatemia

NOVATO, Calif. and TOKYO and LONDON, May 17, 2018 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products fo...

FDA Approves Crysvita, The First Therapy for X-Linked Hypophosphatemia, A Rare Inherited Form of Rickets

NOVATO, Calif. and TOKYO and LONDON, April 17, 2018 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel produ...

BRIEF—Aevi Genomic Medicine expands collaboration with Kyowa Hakko Kirin

USA-based Aevi Genomic Medicine has expanded its collaboration with Japan’s Kyowa Hakko Kirin with…

Kyowa Hakko Kirin Co., Ltd. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 16022018] Prices from USD $350

Kyowa Hakko Kirin Co., Ltd. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Kyowa Hakko Kirin Co., Ltd. Mergers Acquisitions MA, Partnerships Alliances an...

Fujifilm Kyowa Kirin Biologics arbeitet mit Mylan zusammen an Vermarktung von Biosimilar zu Humira (Adalimumab)

Fujifilm Kyowa Kirin Biologics Co. Ltd. gab heute bekannt, dass das Unternehmen mit Mylan N.V. (NASDAQ:MYL) zusammenarbeiten wird, um FKB327, ein von Fujifilm Kyowa Kirin Biologics entwickeltes Bi...

Parkinson Partners, PTV News: Jun 03, 2010

Biovail and Kyowa Hakko Kirin hook up in drug development deal

Drugs and Medications [0 Results]

None

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Burosumab: First Global Approval.

Burosumab (Crysvita; Kyowa Hakko Kirin Co., Ltd. and Ultragenyx Pharmaceutical Inc.) is a fully human monoclonal antibody directed at fibroblast growth factor 23 (FGF23). Excessive FGF23 production ha...

Clinical Trials [0 Results]

None

Companies [17 Associated Companies listed on BioPortfolio]

Kyowa Hakko Kirin Co. Ltd.

Kyowa Hakko Kirin Co., Ltd.

Kyowa Pharmaceutical, Inc

From its foundation in 1949, Kyowa Hakko has been a global leader in the pharmaceutical industry. Today, Kyowa's expertise extends to the United States through Kyowa Pharmaceutical, Inc. headquartered...

Kyowa Hakko

Kyowa Hakko USA

More Information about "Kyowa Hakko Kirin Co. Ltd." on BioPortfolio

We have published hundreds of Kyowa Hakko Kirin Co. Ltd. news stories on BioPortfolio along with dozens of Kyowa Hakko Kirin Co. Ltd. Clinical Trials and PubMed Articles about Kyowa Hakko Kirin Co. Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Kyowa Hakko Kirin Co. Ltd. Companies in our database. You can also find out about relevant Kyowa Hakko Kirin Co. Ltd. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record